

# Conference on Establishment of RACTHERA, the Regenerative Medicine and Cell Therapy Business Joint Venture

Keiichi Iwata – President, Sumitomo Chemical Co., Ltd.  
Toru Kimura – President, Sumitomo Pharma Co., Ltd.

December 17, 2024



Change and Innovation

~ with the **Power** of Chemistry ~

Long-term vision and positioning of each business sector

# Innovative Solution Provider

~A company that solves social issues with innovative technology~



**Food**

Achieve regenerative

Agro & Life Solutions



**ICT**

Innovate IT

ICT & Mobility Solutions



**Healthcare**

Spread leading-edge medicine

Advanced Medical Solutions



**Environment**

Reduce environmental impact

Essential & Green Materials



positioning

**Growth drivers**

Leading short-term growth with a focus on crop protection products and semiconductor materials

**New growth areas**

Cultivating as the third pillar to take off after 2030

**Core domains**

Transitioning to a solution business primarily based on technology licensing

# Full entry into the regenerative medicine & cell therapies business

## Regenerative medicine & cell therapies business

### Market

- The global market for cell therapies was estimated to be worth approximately **\$2.0** billion as of 2022.
- It is expected to continue growing at an annual rate of **10% to 15%** in the coming years.

### Advantage

 **Sumitomo Pharma**

- The technologies and advanced knowledge acquired through their activities as a front runner in regenerative medicine and cell therapy
  - ◆ **Developing the world's first iPS cell-derived cell therapy (Parkinson's disease)**
  - ◆ **October 2021: Approval of RETHYMIC® (with approximately 40 procedures already performed) (pediatric congenital athymia)**



 **SUMITOMO CHEMICAL**


- Development support based on expertise in industrial engineering, analysis and evaluation, and quality management
- Resources at the Environmental Health Science Laboratory and the Bioscience Research Laboratory

The entire Sumitomo Chemical Group is promoting development and business expansion.  
We aim for a business scale of over **350<sup>※</sup>** billion yen by the late 2030s

※ The estimation of the business value assumes that the multiple products that are under development will be successfully launched and does not make any adjustment based on probability of success

# The long-term goals of the Advanced Medical Solutions Sector

## Advanced Medical Solutions Sector



(From the Management Strategy Briefing Materials on April 30, 2024. The estimation of the regenerative medicine & cell therapies business makes adjustments based on the probability of success.)

### Cautionary Statement

Statements made in this document with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it and involve risks and uncertainties.

The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.